Clinical trial · no report yet · Phase 3
postMONARCH
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
- NCT05169567 ↗
- Active not recruiting
- Eli Lilly and Company
- 225 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 104 | |
| Podcasts | 74 | |
| X threads | 46 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Neoplasm; Neoplasm Metastasis
- Interventions
- Abemaciclib; Fulvestrant; Placebo
- Arms
- Arm A: Abemaciclib plus Fulvestrant · Experimental
- Arm B: Placebo plus Fulvestrant · Active comparator
- Enrollment
- 368
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Eli Lilly and Company
- Start
- Mar 11, 2022
- Primary completion
- Feb 8, 2024
- Results posted
- Yes
- Registry record
- NCT05169567 · updated Oct 6, 2026
Publications
linked from the registry- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643. PubMed 40141282
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18. PubMed 39693591